• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性B细胞对放射性标记抗μ抗体的细胞内分解代谢

Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.

作者信息

Geissler F, Anderson S K, Venkatesan P, Press O

机构信息

Department of Biological Structure, University of Washington, Seattle 98195.

出版信息

Cancer Res. 1992 May 15;52(10):2907-15.

PMID:1581908
Abstract

The endocytosis and degradation of 125I-labeled anti-mu monoclonal antibody DA4-4 by a Burkitt's lymphoma cell line was investigated using biochemical, chromatographic, electrophoretic, radioautographic, and electron microscopic techniques. 125I-DA4-4 was rapidly internalized by Ramos cells and routed from endosomes to lysosomes. Proteolysis of radiolabeled antibodies began in a late endosomal compartment, but lysosomes were primarily responsible for the terminal degradation of 125I-DA4-4. Catabolism of 125I-DA4-4 could be inhibited by 74-95% by blocking its delivery to late endosomes and lysosomes by incubation at 18 degrees C, by neutralizing the pH in intracellular organelles with monensin or ammonium chloride, or by inhibiting lysosomal enzymes with leupeptin. Radiolabeled antibodies synthesized using the chloramine T or Iodo-Gen techniques were degraded three times faster than conjugates made using a nonmetabolizable 125I-tyramine cellobiose adduct. Five major intermediate metabolites (Mr 48,000, 42,000, 25,000, 15,000, and 10,000) were generated during the intracellular catabolism of 125I-DA4-4, but 125I-tyrosine was responsible for 95% of the small-molecular-weight metabolites released by cells into the culture medium. We anticipate that a full comprehension of the catabolism of radiolabeled antibodies by tumor cells will make possible the development of clinical interventions which will enhance the retention of radioimmunoconjugates by hematologic malignancies and improve the efficacy of radioimmunotherapy.

摘要

运用生化、色谱、电泳、放射自显影及电子显微镜技术,对伯基特淋巴瘤细胞系摄取及降解¹²⁵I标记的抗μ单克隆抗体DA4-4的过程进行了研究。¹²⁵I-DA4-4被Ramos细胞迅速内化,并从内体转运至溶酶体。放射性标记抗体的蛋白水解始于晚期内体区室,但溶酶体是¹²⁵I-DA4-4最终降解的主要场所。通过在18℃孵育阻断其向晚期内体和溶酶体的转运、用莫能菌素或氯化铵中和细胞内细胞器的pH值,或用亮抑酶肽抑制溶酶体酶,¹²⁵I-DA4-4的分解代谢可被抑制74%至95%。用氯胺T或碘甘醚技术合成的放射性标记抗体的降解速度比使用不可代谢的¹²⁵I-酪胺纤维二糖加合物制备的缀合物快三倍。¹²⁵I-DA4-4细胞内分解代谢过程中产生了五种主要中间代谢产物(分子量分别为48,000、42,000、25,000、15,000和10,000),但¹²⁵I-酪氨酸占细胞释放到培养基中的小分子代谢产物的95%。我们预计,全面了解肿瘤细胞对放射性标记抗体的分解代谢将有助于开发临床干预措施,提高血液系统恶性肿瘤对放射免疫缀合物的保留率,并提高放射免疫治疗的疗效。

相似文献

1
Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.恶性B细胞对放射性标记抗μ抗体的细胞内分解代谢
Cancer Res. 1992 May 15;52(10):2907-15.
2
Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores.
Cancer Res. 1990 Feb 15;50(4):1243-50.
3
Degradation of a monoclonal anti-mu chain antibody in a human surface IgM-positive B cell line starts in prelysosomal vesicle.一种单克隆抗μ链抗体在人表面IgM阳性B细胞系中的降解始于前溶酶体囊泡。
J Immunol. 1988 Nov 1;141(9):2951-8.
4
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.癌细胞对碘 - 125、钇 - 90和铟 - 111放射性免疫缀合物的代谢及保留情况比较
Cancer Res. 1996 May 1;56(9):2123-9.
5
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Cancer Res. 1989 Sep 1;49(17):4906-12.
6
Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells.白血病T细胞对放射性标记抗CD3抗体的细胞内分解代谢
Cell Immunol. 1991 Oct 1;137(1):96-110. doi: 10.1016/0008-8749(91)90060-o.
7
Lysosomal and endosomal heterogeneity in the liver: a comparison of the intracellular pathways of endocytosis in rat liver cells.肝脏中的溶酶体和内体异质性:大鼠肝细胞内吞作用细胞内途径的比较
Hepatology. 1991 Feb;13(2):254-9.
8
Internalization and processing of antibodies to surface antigens on human B cells. Monoclonal anti-IgM antibodies are processed differently than monoclonal antibodies towards non-Ig surface receptors.人B细胞表面抗原抗体的内化与加工。单克隆抗IgM抗体与针对非Ig表面受体的单克隆抗体的加工方式不同。
Eur J Immunol. 1986 Mar;16(3):286-91. doi: 10.1002/eji.1830160314.
9
Activation of human B cells and inhibition of their terminal differentiation by monoclonal anti-mu antibodies.单克隆抗μ抗体对人B细胞的激活及其终末分化的抑制作用。
J Immunol. 1985 Jul;135(1):192-9.
10
Genesis of B lymphocytes in the bone marrow: extravascular and intravascular localization of surface IgM-bearing cells in mouse bone marrow detected by electron-microscope radioautography after in vivo perfusion of 125I anti-IgM antibody.骨髓中B淋巴细胞的起源:体内灌注¹²⁵I抗IgM抗体后,通过电子显微镜放射自显影检测小鼠骨髓中携带表面IgM细胞的血管外和血管内定位。
Am J Anat. 1984 Jul;170(3):349-65. doi: 10.1002/aja.1001700310.

引用本文的文献

1
Late-stage labeling of diverse peptides and proteins with iodine-125.用碘-125对多种肽和蛋白质进行后期标记。
J Pharm Anal. 2025 Jul;15(7):101198. doi: 10.1016/j.jpha.2025.101198. Epub 2025 Jan 17.
2
A comparison of Cu-labeled bi-terminally PEGylated A20FMDV2 peptides targeting integrin αβ.Cu 标记的双端聚乙二醇化 A20FMDV2 肽靶向整合素 αβ 的比较。
Oncotarget. 2022 Feb 16;13:360-372. doi: 10.18632/oncotarget.28197. eCollection 2022.
3
Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer.
组织因子靶向免疫正电子发射断层显像及间变性甲状腺癌的放射免疫治疗
Adv Sci (Weinh). 2020 May 17;7(13):1903595. doi: 10.1002/advs.201903595. eCollection 2020 Jul.
4
Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders-An Update.用于肿瘤疾病成像的抗体免疫正电子发射断层显像/单光子发射计算机断层显像放射性药物的进展——最新情况
Cancers (Basel). 2020 Jul 11;12(7):1868. doi: 10.3390/cancers12071868.
5
SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human.用于建立人类相关临床前模型的犬自发性弥漫性大B细胞淋巴瘤靶向CD22的SPECT-CT成像
Front Oncol. 2020 Feb 7;10:20. doi: 10.3389/fonc.2020.00020. eCollection 2020.
6
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals.一种基于快速珠的放射性配体结合分析测定,用于测定靶结合分数和放射性药物的质量控制。
Nucl Med Biol. 2019 Apr;71:32-38. doi: 10.1016/j.nucmedbio.2019.04.005. Epub 2019 May 3.
7
Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.了解用于核成像的放射免疫缀合物的体内命运。
J Labelled Comp Radiopharm. 2018 Jul;61(9):672-692. doi: 10.1002/jlcr.3628. Epub 2018 May 14.
8
Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination.放射性碘化药物的设计:影响体内脱碘代谢稳定性的结构特征
European J Org Chem. 2017 Jun 30;2017(24):3387-3414. doi: 10.1002/ejoc.201601638. Epub 2017 Apr 26.
9
Radioimmunotherapy of human tumours.人类肿瘤的放射免疫疗法。
Nat Rev Cancer. 2015 Jun;15(6):347-60. doi: 10.1038/nrc3925.
10
N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.N-琥珀酰亚胺基碘苯甲酸胍甲基蛋白质放射性卤化剂:异构体取代对放射性标记和靶细胞滞留的影响。
Nucl Med Biol. 2014 Nov-Dec;41(10):802-12. doi: 10.1016/j.nucmedbio.2014.07.005. Epub 2014 Aug 1.